Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

PURPOSE: Resistance to trastuzumab therapy is linked to phosphoinositol 3-kinase (PI3K) pathway activation. One key downstream effector and regulator of this pathway is the mechanistic target of rapamycin (mTOR). In 2011, a phase I/II study evaluated the combination of trastuzumab and everolimus (a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Cancer Res Clin Oncol
Autori principali: de Oliveira Taveira, Mateus, Nabavi, Sheida, Wang, Yuker, Tonellato, Peter, Esteva, Francisco J., Cantley, Lewis C., Wulf, Gerburg M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2017
Soggetti:
Original Article – Clinical Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486569/
https://ncbi.nlm.nih.gov/pubmed/28247034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-017-2358-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi